Results 11 to 20 of about 8,866 (177)

Disseminated fungal infection in a patient receiving zanubrutinib

open access: yesClinical Case Reports, 2023
Key Clinical Message We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second‐generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression‐related side effects.
Madalyn Walsh   +3 more
doaj   +1 more source

Role of Bruton's tyrosine kinase in B cells and malignancies [PDF]

open access: yes, 2018
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primary
Dammeijer, F. (Floris)   +2 more
core   +13 more sources

Btk regulates macrophage polarization in response to lipopolysaccharide [PDF]

open access: yes, 2014
Bacterial Lipopolysaccharide (LPS) is a strong inducer of inflammation and does so by inducing polarization of macrophages to the classic inflammatory M1 population.
A Arranz   +79 more
core   +9 more sources

The Different Faces of Chronic Lymphocytic Leukemia -Two Clinical Cases [PDF]

open access: yesJournal of Biomedical & Clinical Research, 2020
Chronic lymphocytic leukemia is one of the most common types of leukemia affecting adults over 65 years of age [1]. The disease is a part of the so-called indolent lymphomas and has a variable clinical course, defined by many factors.
Vanya Popova   +5 more
doaj   +3 more sources

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

open access: yes, 2014
Pharmacological targeting of BTK using ibrutinib has recently shown encouraging clinical activity in a range of lymphoid malignancies. Recently we reported that ibrutinib inhibits human acute myeloid leukemia (AML) blast proliferation and leukemic cell ...
Bowles, Kristian M   +6 more
core   +2 more sources

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia [PDF]

open access: yes, 2014
Bruton's tyrosine kinase (BTK) is a cytoplasmic protein found in all hematopoietic cell lineages except for T cells. BTK mediates signalling downstream of a number of receptors.
Advani   +59 more
core   +1 more source

Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor. [PDF]

open access: yes, 2014
Btk and Etk/BMX are Tec-family non-receptor tyrosine kinases. Btk has previously been reported to be expressed primarily in B cells and has an important role in immune responses and B-cell malignancies.
Bhardwaj, G   +16 more
core   +2 more sources

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

open access: yesPLoS ONE, 2017
Activated B-cell-like diffuse large B-cell lymphoma relies on B-cell receptor signaling to drive proliferation and survival. Downstream of the B-cell receptor, the key signaling kinases Bruton's tyrosine kinase and phosphoinositide 3-kinase δ offer ...
Anella Yahiaoui   +9 more
doaj   +1 more source

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

open access: yesNature Communications, 2020
PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dual ...
Wen-Hao Guo   +18 more
doaj   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

open access: yes, 2016
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy